AdAlta and XL-protein execute commercial license agreement
FREISING Germany, 13 November, 2017: XL-protein GmbH is pleased…
Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates
Freising, July 26, 2017 /XL-protein/ -- Jazz Pharmaceuticals…
AdAlta and XL-protein announce collaboration to develop a long acting version of its lead fibrosis drug candidate AD-114 using PASylation® Technology
Melbourne, Australia and FREISING, Germany, 7 November 2016:…